GlassScriptPhysician profile
John W Gnann
NPI 1467498659
$39,148.55
in general payments reported to CMS, 2019-2025
6 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,382 · 2020: $2,661 · 2021: $11K · 2024: $7,500 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,572.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19,003.55 | 2019-2025 | |
| Biocryst Pharmaceuticals, INC. | $14,550.00 | 2021-2025 | |
| Merck Kgaa | $2,720.00 | 2021 | |
| Modernatx, INC. | $2,425.00 | 2025 | |
| Perrigo Company Plc | $450.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gnann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.